Currently, there are 195.44M common shares owned by the public and among those 195.06M shares have been available to trade.
The company’s stock has a 5-day price change of -6.46% and 74.71% over the past three months. ESPR shares are trading 1.67% year to date (YTD), with the 12-month market performance up to 104.03% higher. It has a 12-month low price of $1.35 and touched a high of $3.94 over the same period. ESPR has an average intraday trading volume of 4.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.51%, 29.90%, and 35.55% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Esperion Therapeutics Inc (NASDAQ: ESPR) shares accounts for 65.84% of the company’s 195.44M shares outstanding.
It has a market capitalization of $598.98M and a beta (3y monthly) value of 0.97. The earnings-per-share (ttm) stands at -$0.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.50% over the week and 10.81% over the month.
Earnings per share for the fiscal year are expected to increase by 85.15%, and 210.03% over the next financial year. EPS should shrink at an annualized rate of 16.90% over the next five years, compared to 23.09% over the past 5-year period.
Looking at the support for the ESPR, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on June 20, 2024, with the firm’s price target at $2.50. BofA Securities on their part issued Buy rating on June 15, 2023.
